Anti-EGFR therapies in nasopharyngeal carcinoma
Xishan Chen, Renba Liang, Xiaodong Zhu
Abstract
Nasopharyngeal carcinoma (NPC) is a common malignant tumor in Southern China and South-East Asia. Regardless of initiative high response to radiotherapy, parts of patients still have relapses and metastases. It is reported that epidermal growth factor receptor (EGFR) is highly expressed in most of NPC and is a poor prognostic factor. Targeting EGFR therapies including monoclonal antibodies and EGFR tyrosine kinase inhibitors (EGFR-TKIs), offer different benefits and toxicities for patients with NPC. Herein, we summarize the clinical evidence of anti-EGFR therapies in the management of NPC and provide a direction for the treatment and research of NPC in the future.
Topics & Concepts
Nasopharyngeal carcinomaMedicineEpidermal growth factor receptorOncologyEGFR inhibitorsRadiation therapyMonoclonal antibodyInternal medicineTyrosine kinaseCancer researchCarcinomaCancerImmunologyAntibodyReceptorLung Cancer Treatments and MutationsLung Cancer Research StudiesHead and Neck Cancer Studies